A detailed history of Creative Planning transactions in Altimmune, Inc. stock. As of the latest transaction made, Creative Planning holds 18,411 shares of ALT stock, worth $140,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,411
Previous 3,000 513.7%
Holding current value
$140,107
Previous $19,000 494.74%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$5.5 - $8.1 $33,726 - $49,669
6,132 Added 49.94%
18,411 $113,000
Q2 2024

Aug 15, 2024

BUY
$5.91 - $10.23 $2,955 - $5,115
500 Added 4.24%
12,279 $81,000
Q1 2024

May 10, 2024

SELL
$8.22 - $13.81 $2,466 - $4,143
-300 Reduced 2.48%
11,779 $119,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $25,849 - $140,357
12,079 New
12,079 $135,000
Q4 2020

Jan 29, 2021

SELL
$7.84 - $14.22 $203,204 - $368,568
-25,919 Closed
0 $0
Q3 2020

Nov 05, 2020

BUY
$9.93 - $33.26 $257,375 - $862,065
25,919 New
25,919 $342,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $373M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.